VivoSeq
Other

Blood Disease

8

Pipeline Programs↗

1

Active Trials↗

4

Companies Involved↗

Blood Disease is an early-stage landscape with 8 programs across 4 companies. The most active players are Alnylam Pharmaceuticals, Sanofi, Roche.

Intelligence

Pipeline Metrics

Competitive Density

34/100

Pipeline Velocity

6/100

Mech. Concentration

20/100

Completion Rate

67/100

Attrition Rate

20/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

2 programs

Phase 2Sanofi logo

Sanofi

1 program

Phase 2Roche logo

Roche

1 program

PreclinicalE

Eastern Cooperative Oncology Group

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

11programs
Small molecule655%
Cell therapy327%
Monoclonal antibody19%
Protein / enzyme19%

Modality classified for 100% of 11 pipeline programs.

Analysis

Trial Status

5

clinical trials

Completed2 · 40%
Terminated1 · 20%
Unknown status1 · 20%
Not yet recruiting1 · 20%

Clinical Trials

Trial Activity

Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases
Terminated·FFred Hutchinson Cancer Center·Phase 2·NCT00450983·1 enrolled
Population Pharmacokinetic-pharmacodynamic Study of Rituximab in Children With Blood Diseases
Unknown status·TThe Affiliated Hospital of Qingdao University·N/A·NCT05324917·20 enrolled
Chimeric Antigen Receptor T-cell and Cellular Therapies for the Treatment of cAncer or BLood Diseases: Evaluation of Reporting of Adverse Events
Completed·GGroupe Hospitalier Pitie-Salpetriere·N/A·NCT04279470·100,000 enrolled
Study Evaluating the Efficacy of Allogeneic Transplant Conditioning With Adaptive Dose Busulfan Intravenous (Busilvex®) in Patients at High Risk of Carrying Blood Diseases
Completed·IInstitut Paoli-Calmettes·Phase 2·NCT02483325·33 enrolled
TCRαβ+ and CD19+ Depleted Hematopoietic Stem Cell Transplant From Closely Matched Unrelated Donors or Haploidentical Related Donors for Hematologic Diseases in Children and Young Adults
Not yet recruiting·UUniversity of Wisconsin, Madison·Phase 1·NCT04806347·12 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)